Cart
sales@molnova.com
KDM5A covalent inhibitor N71
CAS No. ——
KDM5A covalent inhibitor N71( —— )
Catalog No. M17072 CAS No. ——
KDM5A covalent inhibitor N71 is an irreversible KDM5A inhibitor (IC50=0.22 uM) that covalently interacts with Cys481.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameKDM5A covalent inhibitor N71
-
NoteResearch use only, not for human use.
-
Brief DescriptionKDM5A covalent inhibitor N71 is an irreversible KDM5A inhibitor (IC50=0.22 uM) that covalently interacts with Cys481.
-
DescriptionKDM5A covalent inhibitor N71 is an irreversible KDM5A inhibitor (IC50=0.22 uM) that covalently interacts with Cys481, >20-fold selectivity over KDM4A.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetHistone Demethylase
-
RecptorHistone Demethylase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight522.664
-
Molecular FormulaC28H34N4O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name(E)-2-((3-(4-(dimethylamino)but-2-enamido)phenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Horton JR, et al. J Med Chem. 2018 Nov 15. doi: 10.1021/acs.jmedchem.8b01219.
molnova catalog
related products
-
CBB3001
CBB3001 (CBB-3001) is a novel potent, selective histone demethylase LSD1 inhibitor with IC50 of 21.25 uM.
-
SGC-iMLLT
SGC-iMLLT is a potent and selective MLLT1/3-histone interactions inhibitor(IC50 = 0.26 μM),and is a first-in-class chemical probe displaying cellular target engagement of MLLT1(Kd = 0.129?μM) and MLLT3(Kd = 0.077?μM).
-
C 21
Selective protein arginine methyltransferase 1 (PRMT1) inhibitor (IC50 = 1.8 μM). Exhibits five-fold selectivity for PRMT1 over PRMT6 and >250-fold selectivity over PRMT3 and CARM1.
